(Total Views: 512)
Posted On: 08/26/2020 10:31:28 AM
Post# of 154029
I don't intend to be difficult, but all patients in the trials continue to receive standard of care.
Treatments don't stop when patients enroll in a trial, either arm.
Patients are not given a shot of leronlimab and ripped from the ventilator to see if they live or die.
The verbiage on the clinical trials website could be more explicit, but the permissible pharmaceutical treatments that patients may continue to receive during the CD12 trial are noted as follows.
Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care
It is easy to think that patients may be short changes in a trial, but this is completely untrue. The only downside is that while all patients receive the standard of care and are therefore no worse off for their participation, only 67% receive leronlimab as an additional treatment.
Treatments don't stop when patients enroll in a trial, either arm.
Patients are not given a shot of leronlimab and ripped from the ventilator to see if they live or die.
The verbiage on the clinical trials website could be more explicit, but the permissible pharmaceutical treatments that patients may continue to receive during the CD12 trial are noted as follows.
Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care
It is easy to think that patients may be short changes in a trial, but this is completely untrue. The only downside is that while all patients receive the standard of care and are therefore no worse off for their participation, only 67% receive leronlimab as an additional treatment.
(4)
(0)
